GlassScriptPhysician profile
Jesse Aleman-Ortiz
NPI 1104077213
$9,852.03
in general payments reported to CMS, 2019-2025
29 companies · $1,579 in 2025
The $1,579 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,633 · 2020: $678 · 2021: $1,799 · 2022: $891 · 2023: $1,325 · 2024: $1,947 · 2025: $1,579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,716 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,716.39 |
| Education | $133.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,080.95 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $1,333.07 | 2021-2024 | |
| Glaxosmithkline, LLC. | $1,299.00 | 2019-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $893.35 | 2019-2025 | Ofev, Jascayd |
| Actelion Pharmaceuticals US, INC. | $470.41 | 2022-2025 | Uptravi, Opsynvi, Opsumit |
| Genzyme Corporation | $451.83 | 2021-2025 | |
| Mylan Specialty L.P. | $432.62 | 2019-2024 | Yupelri, Yupelri |
| Janssen Pharmaceuticals, INC | $400.16 | 2019-2025 | Xarelto, Uptravi, Tecvayli |
| Takeda Pharmaceuticals U.S.A., INC. | $399.44 | 2022-2025 | Glassia, Cuvitru, Hyqvia |
| Ani Pharmaceuticals, INC. | $329.97 | 2023-2025 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $253.59 | 2024-2025 | Capvaxive, Winrevair |
| Jazz Pharmaceuticals INC. | $226.75 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $148.00 | 2019-2021 | |
| United Therapeutics Corporation | $146.81 | 2019-2025 | Tyvaso |
| Eli Lilly Export S.A. Puerto Rico Branch | $144.63 | 2019-2025 | Zepbound |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pbg Puerto Rico LLC | $126.64 | 2019-2024 | |
| Amgen INC. | $111.72 | 2022-2025 | Tezspire |
| Mallinckrodt Enterprises LLC | $94.63 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $89.57 | 2021 | |
| Mylan LLC | $89.11 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $66.37 | 2024 | Acthar |
| Harmony Biosciences LLC | $50.36 | 2024-2025 | |
| Olympus Latin America, INC. | $48.78 | 2022 | |
| Chiesi USA, INC. | $44.63 | 2021-2022 | |
| Viatris Specialty LLC | $41.38 | 2025 | Yupelri |
| Sandoz INC. | $31.02 | 2024-2025 | Treprostinil |
| Pfizer Pharmaceuticals LLC | $16.95 | 2019 | |
| Shire North American Group INC | $16.08 | 2019 | |
| Insmed, INC. | $14.21 | 2024 | Arikayce |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Aleman-Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.